SAN RAMON, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report second quarter 2024 financial results on Thursday, May 30, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
The dial-in number for the call is 800-715-9871 and the conference ID is 1712676. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$92.26 |
Daily Change: | -1.18 -1.26 |
Daily Volume: | 293,722 |
Market Cap: | US$18.410B |
December 17, 2024 December 05, 2024 September 03, 2024 August 28, 2024 August 01, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB